David Stipp

Recent posts

GTC Biotherapeutics, Racing Against Time to Prove the Worth of “Pharming”
As a rule, getting a drug on the market turns a biotech startup from a buck bonfire into a cash cow—or at least a cash calf. But rules tend to get... Read more »
GTC Biotherapeutics Drug Passes Clinical Milestone, Helping Blaze the Trail for U.S. “Pharming”
GTC Biotherapeutics (NASDAQ: GTCB), which bioengineers goats to secrete drugs in their milk, announced late yesterday that its groundbreaking medicine for a rare blood-clotting disorder cleared the main hurdle in... Read more »
ImmunoGen’s Mitch Sayare on What Sustains a Company—and its CEO—Through Decades of Starting Up
Call it the 27-year-old startup: ImmunoGen, one of biotech’s oldest companies, has yet to get a drug on the market more than a quarter century after its formation in 1981.... Read more »
Ischemix is Stepping Out of the Shadows to Confront Cardiology’s Dirty Little Secret
No doctors thwart the Reaper more often than cardiologists, who routinely pull heart-attack victims back from the brink with artery-opening procedures. But their god-like powers suddenly fade after coronary arteries are... Read more »
Resolvyx Pharmaceuticals: Fish-Oil Mystery Solved, Blockbuster Drugs to Follow?
If you haven’t considered eating more fish or taking fish-oil pills by now, you’re probably very young, just in from Mars, or both. The case for the health benefits of omega-3... Read more »
The Boston-China Biopharma Connection
The Great Bubble is dead and gone, but like Elvis it’s still occasionally sighted. Daytraders, for instance, could have sworn it was gyrating across their screens when WuXi PharmaTech recently went... Read more »
Can ToleRx Escape the Autoimmunity-Drug-Development Deathtrap?
“Like does not like like that is obnoxious.” Poet Marianne Moore wasn’t thinking of autoimmune diseases when she penned this line but it memorably captures the strife behind them—when our immune... Read more »
Biotech Takes on Toxic Drugs
Nothing robs pharma officials of more sleep than unexpected toxicity linked to one of their companies’ medicines. Recently they’ve lost more shuteye than ever as reports on cardiac risks of widely-used... Read more »
Aveo’s Better Mousetraps for Cancer Drugs
Oncology researchers are fond of saying that if you’re a mouse with cancer, they’ve found drugs that can cure you. Scientists at Cambridge-based Aveo Pharmaceuticals have even better news: They’ve developed... Read more »

Page 1 of 1

Underwriters and Partners

Xpertise: Watch + Learn

From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Facing an Uncertain Future
Xconomy

Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed

From Our Editors · Special Report
2019 Blockchain Outlook — Reality Check
Reality Check
Xconomy

From Our Advertisers

Wisconsin helps biotech company raise $20 million
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

IDG Tech Network

Protected by Carbonite

Eventbrite - events made easy